Literature DB >> 3145120

Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly.

C de la Piedra1, J Larrañaga, N Castro, C Horcajada, A Rapado, J L Herrera Pombo, E Carbó.   

Abstract

Plasma osteocalcin (BGP), growth hormone (GH), and somatomedin C(SmC) were measured in 12 patients with acromegaly [7 clinically active (aA), 5 cured (cA)] and 9 control subjects (C). Basal plasma values for the three parameters were higher in aA than in C and in cA. No significant difference was found between cA and C. A significant linear correlation between BGP and GH and between BGP and SmC was obtained. These results suggest an effect of GH on BGP synthesis, possibly mediated by SmC, although a direct effect of GH on bone cannot be excluded.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3145120     DOI： 10.1007/bf02555167

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  10 in total

1.  Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.

Authors:  P D Delmas; B Demiaux; L Malaval; M C Chapuy; P J Meunier
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

2.  Increase in serum osteocalcin concentration is a slow indicator of therapeutic effect in children treated for somatotropin deficiency.

Authors:  G Lindstedt; L Wejkum; P A Lundberg
Journal:  Clin Chem       Date:  1986-08       Impact factor: 8.327

3.  Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone.

Authors:  P A Price; M K Williamson; J W Lothringer
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

4.  Iliac crest bone mass and remodelling in acromegaly.

Authors:  J Halse; F Melsen; L Mosekilde
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05

Review 5.  Pituitary tumors secreting growth hormone and prolactin.

Authors:  S Melmed; G D Braunstein; R J Chang; D P Becker
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

6.  [Serum levels of osteocalcin in hypercalcemia caused by primary hyperparathyroidism and in tumor hypercalcemia].

Authors:  C de la Piedra; A Rapado; P Esbrit
Journal:  Rev Clin Esp       Date:  1985-11       Impact factor: 1.556

7.  Serum bone GLA-protein in growth hormone deficient children.

Authors:  P D Delmas; P Chatelain; L Malaval; G Bonne
Journal:  J Bone Miner Res       Date:  1986-08       Impact factor: 6.741

8.  Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy.

Authors:  C de la Piedra; V Toural; A Rapado
Journal:  Scand J Clin Lab Invest       Date:  1987-10       Impact factor: 1.713

9.  Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry.

Authors:  P D Delmas; B Demiaux; L Malaval; M C Chapuy; C Edouard; P J Meunier
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

10.  Changes in plasma bone GLA protein during treatment of bone disease.

Authors:  L J Deftos; J G Parthemore; P A Price
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333
  10 in total
  9 in total

Review 1.  Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?

Authors:  I Chiodini; V Trischitta; V Carnevale; A Liuzzi; A Scillitani
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

2.  Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.

Authors:  M J Kayath; J G Vieira
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

Review 4.  Musculoskeletal Effects of Altered GH Action.

Authors:  Jonathan A Young; Shouan Zhu; Edward O List; Silvana Duran-Ortiz; Yosri Slama; Darlene E Berryman
Journal:  Front Physiol       Date:  2022-05-19       Impact factor: 4.755

5.  Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.

Authors:  M Terzolo; A Piovesan; G Osella; A Pia; G Reimondo; C Pozzi; C Raucci; M Torta; P Paccotti; A Angeli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

6.  Serum bone Gla protein as a marker of bone turnover in acromegaly.

Authors:  M Marazuela; B Astigarraga; M J Tabuenca; J Estrada; F Marín; T Lucas
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

7.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

Review 8.  Renal effects of growth hormone. II. Electrolyte homeostasis and body composition.

Authors:  G D Ogle; A R Rosenberg; G Kainer
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.